Pharmacokinetics and Pharmacodynamics of SM-20302, a GPIIb/IIIa Receptor Antagonist, in Anesthetized Dogs

Authors:
  • JHJinbao Huang
    Jinbao Huang
  • WSWayne J. Shiu
    Wayne J. Shiu
  • KSKumi Saito
    Kumi Saito
  • MKMunekiyo Kaneko
    Munekiyo Kaneko
  • YSYoshikazu Saitoh
    Yoshikazu Saitoh
  • BLBenedict R. Lucchesi
    Benedict R. Lucchesi

Abstract
We examined the pharmacokinetic and pharmacodynamic properties of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. SM-20302 was administered intravenously in doses of 30 (n = 2), 100 (n = 4), 300 (n = 4), and 1,000 μg/kg (n = 4). The half-life of the initial phase was 4 min, and that of the terminal phase was 162-209 min. SM-20302 produced a dose-dependent increase in the initial plasma concentration and the area under concentration-time curve but did not alter the volume of distribution, mean residence time, or plasma clearance. Plasma clearance for SM-20302 ranged from 6.58 to 9.73 ml/min/kg. All doses of SM-20302 inhibited (≥90%) the ex vivo platelet aggregation induced by adenosine diphosphate (ADP) or arachidonic acid (AA) in citrated platelet-rich plasma (cPRP). In heparinized PRP (hPRP), a dose-dependent (44-89%) inhibition was observed. By using a sigmoid Emax model, the in vivo median inhibitory concentration (IC50) for SM-20302 was estimated to be 14-19 ng/ml in cPRP and 79-89 ng/ml in hPRP. To validate the calculated parameters, an infusion regimen was designed for the prevention of coronary artery thrombosis. Infusion of SM-20302 produced 64-67% inhibition of platelets in hPRP and maintained vessel patency despite vessel wall injury. The results suggest that SM-20302 exhibits linear pharmacokinetics and that its ability to inhibit platelet aggregation in hPRP may correlate more accurately with its in vivo antithrombotic efficacy.

This publication has 34 references indexed in Scilit: